Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Olink Bioscience, Invitrogen, AnaSpec

Premium
Sigma-Aldrich last week launched the PhosDecor Fluorescent Phosphoprotein In-Gel Detection Kit for identifying phosphorylated proteins. The kit includes a phosphate specific PhosDecor Stain, specially formulated buffers, and a positive control to validate system performance.
 

 
Olink Bioscience this week released the Duolink reagent kit for the detection of single molecule events such as protein interactions in unmodified cells and tissue sections. Duolink is based on the company’s proprietary in situ Proximity Ligation Assay technology. The kits are available for use with any combination of two primary antibodies raised in mouse, rabbit, or goat.
 

 
Invitrogen launched the Dynabeads M-270 Immunoassay this week. The beads are used to immobilize antigens such as proteins and peptides for in vitro diagnostic magnetic bead-based immunoassay applications. The hydrophilic surface of the beads “ensures low non-specific binding of serum proteins that would otherwise interfere with the assay,” the company said in a statement, adding they disperse well, are easily handled in a variety of buffers, and do not inhibit enzymatic activity.
 

 
AnaSpec this week released a new line of SensoLyte Anti-MOG ELISA kits, which the company said is the industry’s first anti-MOG ELISA kits. AnaSpec also added 72 antibodies to its collection of catalog antibodies. They include Anti-Chromogranin A; Anti-p19INK4d, and Anti-Protein Kinase C.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.